X

Drug Profile

Research programme: AGE Formation Inhibitors - Synvista

Alternative Names: ALT-946

Latest Information Update: 07 Apr 2009

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alteon
Developer Synvista Therapeutics
Class Acetamides; Antihyperglycaemics; Hydrazines; Small molecules
Mechanism of Action Advanced glycosylation end product inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Diabetic nephropathies

Most Recent Events

24 Jul 2007 Alteon is now called Synvista Therapeutics
22 Nov 2002 A preclinical study has been added to the Diabetes pharmacodynamics section
08 May 2001 Preclinical development for Diabetic nephropathies in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com